Exploring Key Insights of the Pulmonary Or Respiratory Drug Delivery Market: Growth Prospects, Emerging Trends, and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Rapidly is the Pulmonary Or Respiratory Drug Delivery Market Expected to Expand Between 2025 and 2034 Based on Current Trends?
There has been a robust expansion in the market size of pulmonary or respiratory drug delivery in the past few years. It is projected to increase from $69.83 billion in 2024 to $76.38 billion in 2025, which equates to a compound annual growth rate (CAGR) of 9.4%. The historical growth of this market is largely due to factors such as the increasing occurrence of asthma, widespread adoption of sophisticated inhalation devices, global increase in healthcare spending, growing awareness about respiratory diseases, and a surge in the number of reported allergic conditions.
The market size of pulmonary or respiratory drug delivery is forecasted to experience robust growth in the coming years. The market is projected to expand to $107.85 billion by 2029, with a compound annual growth rate (CAGR) of 9.0%. The surge during the forecast period could be due to the increasing demand for tailor-made medicine, the growing incidence of chronic respiratory diseases, a heightened focus on telemedicine, an escalation in investments in healthcare infrastructure, and an increase in pharmaceutical product e-commerce. During the forecast period, major trends anticipated include enhancements in particle engineering, the creation of advanced nebulizers, the expansion of liposomal formulations, advancements in computational fluid dynamics, and the maturation of smart inhalers.
How Are the key drivers Contributing to the Expansion of the Pulmonary Or Respiratory Drug Delivery Market?
The escalating incidences of pneumonia are projected to fuel the expansion of the pulmonary or respiratory drug delivery market. Pneumonia, a lung infection, inflames the air sacs and can cause a build-up of fluid or pus, resulting in symptoms such as cough, fever, and breathlessness. The surge in pneumonia incidences can be attributed to factors like aging populations, compromised immune systems, respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria. The pulmonary or respiratory drug delivery approach aids pneumonia patients by directly delivering medications such as antibiotics, bronchodilators, or anti-inflammatory agents to the lungs. This enables a swifter and more potent treatment protocol to alleviate symptoms, curb inflammation, clear infections, and enhance respiratory performance, ultimately leading to quicker recovery and the avoidance of complications. For example, the Centre for Tropical Medicine and Global Health, a UK-based pioneer in healthcare research, indicated a significant surge in pneumonia cases in Kenya in November 2023, touching 793,864 in 2022/2023. Hence, the escalating incidences of pneumonia act as a driving force for the pulmonary or respiratory drug delivery market.
Get Your Free Sample of the Global Pulmonary Or Respiratory Drug Delivery Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp
Which Key Players Are Shaping the Future of the Pulmonary Or Respiratory Drug Delivery Market?
Major companies operating in the pulmonary or respiratory drug delivery market are:
• Merck & Co. Inc._x000D_
• Novartis AG_x000D_
• Thermo Fisher Scientific Inc._x000D_
• AstraZeneca plc_x000D_
• Abbott Laboratories_x000D_
How Are the Latest Trends Influencing the Growth of the Pulmonary Or Respiratory Drug Delivery Market?
Key players in the market of pulmonary or respiratory drug delivery are centering their efforts on technological improvements like intricate drug delivery systems to maximize treatment effectiveness and patient adherence. These complex systems are a breakthrough in technology, optimizing targeted delivery alongside controlled therapeutic agent release that augments drug efficacy as well as patient prognosis. An example of this is seen in July 2023, when Viatris Inc., an American healthcare firm that produces generic and branded drugs, partnered with Kindeva Drug Delivery, L.P., another American firm specializing in drug delivery, to introduce Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol gained approval from the US government’s Food and Drug Administration as the inaugural generic version of AstraZeneca’s Symbicort, a metered-dose inhaler merging budesonide and formoterol, used in the therapy of asthma and chronic obstructive pulmonary disease. Breyna is offered in two potencies – 80 micrograms and 160 micrograms, with formoterol comprising 4.5 micrograms.
Get Instant Access to the Global Pulmonary Or Respiratory Drug Delivery Market Report with Swift Delivery!
What Are the Major Segments of the Pulmonary Or Respiratory Drug Delivery Market and Their Role in Driving Growth?
The pulmonary or respiratory drug delivery market covered in this report is segmented –
1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices
What Regions Are At the Forefront of Pulmonary Or Respiratory Drug Delivery Market Expansion?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can We Define the Pulmonary Or Respiratory Drug Delivery Market and Its Key Components?
Pulmonary or respiratory drug delivery refers to the administration of medication directly into the lungs to achieve rapid absorption, targeted treatment, and reduced systemic side effects for both local and systemic therapeutic effects.
Browse Through More Similar Reports By The Business Research Company:
Pulmonary Arterial Hypertension Global Market Report 2025
https://thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025
Idiopathic Pulmonary Fibrosis Global Global Market Report 2025
https://thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: